lifestyle.phenomena.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Altesa Biosciences Inc.
Altesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026
May 19, 2026
New Altesa BioSciences Data: Vapendavir Demonstrates Anti-Viral Activity Against All Three Rhinovirus Species
May 12, 2026
Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations
May 5, 2026
Altesa BioSciences Selected for Oral Presentation at the American Thoracic Society 2026 International Congress
April 30, 2026
Altesa BioSciences’ Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026
March 19, 2026
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
February 19, 2026